FDA pours cold water on PTC Therapeutics' Duchenne drug application

(Reuters) - PTC Therapeutics Inc has not supplied "persuasive" evidence that its experimental drug to treat a form of Duchenne muscular dystrophy is effective, a preliminary review by scientists at the U.S. Food and Drug Administration concluded.